Main Session
Sep
28
SS 15 - Immunotherapy Integration and Immuno Biomarkers Across Mucosal and Cutaneous SCC
172 - Phase 2 Trial of First-Line Camrelizumab plus Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Oral Squamous Cell Carcinoma: Outcomes and Toxicity Profile
Presenter(s)
Feng Liu, MD - Hunan Cancer Hospital, Changsha, Hunan